On April 8, ABL Bio, a company specializing in bispecific antibodies, announced that Toveximig, a cholangiocarcinoma treatment being developed by its global partner Compass Therapeutics, has been designated as an orphan drug by the U.S. Food and Drug Administration (FDA).


The orphan drug designation system targets rare diseases affecting fewer than 200,000 patients and is designed to encourage the development of treatments in areas with limited drug development. Once designated as an orphan drug, the product is granted a period of market exclusivity in the United States (typically seven years), along with benefits such as tax credits, partial exemption from FDA review fees, clinical trial grants, and regulatory development support.

ABL Bio’s Partner Compass Therapeutics’ Cholangiocarcinoma Drug Toveximig Receives FDA Orphan Drug Designation View original image

Toveximig is a bispecific antibody developed by ABL Bio and licensed to Compass Therapeutics. It works by simultaneously blocking the DLL4 (Delta-like ligand 4) and VEGF-A (Vascular Endothelial Growth Factor-A) signaling pathways, both of which play crucial roles in neovascularization and tumor angiogenesis. According to preclinical and clinical studies, simultaneous inhibition of DLL4 and VEGF-A suppresses tumor cell growth, resulting in strong anticancer effects.


Currently, Compass Therapeutics is conducting the COMPANION-002 phase 2/3 clinical trial in combination with the chemotherapy agent paclitaxel for patients receiving second-line treatment for cholangiocarcinoma. This month, data will be released on key indicators such as overall survival (OS) and progression-free survival (PFS), which have the most significant impact on the FDA’s new drug approval review.



ABL Bio CEO Sanghoon Lee stated, “In April 2024, Compass Therapeutics already received Fast Track Designation from the FDA for Toveximig and has utilized the benefits of the system for its clinical development. Based on the clinical data from COMPANION-002, Compass Therapeutics plans to discuss the next stages of development with the FDA. We expect that this orphan drug designation, following the Fast Track Designation, will have a positive impact on the approval process for Toveximig.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing